Databases: Scientists' and Organizations' Links to Industry
Return to CSPI U.S.
Non-Profit Organizations Receiving Corporate Funding 
Index of Non-Profit Organizations Receiving Corporate Funding
 
SOCIETY FOR HEART ATTACK PREVENTION AND ERADICATION
 

SOCIETY FOR HEART ATTACK PREVENTION AND ERADICATION

Founded in 2001, the Society for Heart Attack Prevention and Eradication (SHAPE), formerly known as the Association for Eradication of Heart Attack, is “an education-based organization that is dedicated to ending the threat of heart attack….Our work is guided by the active participation and support of world renowned cardiovascular specialists and researchers.” Currently the organization is “focused on promoting the SHAPE Guideline, a screening protocol that builds on the old paradigm in cardiology, risk factor detection and treatment.” (http://www.shapesociety.org/site/c.iuIRL8MVJxE/b.2802413/k.AEBB/About.htm, accessed 1/15/08)

The SHAPE guideline appeared in a Pfizer-funded supplement to the July 2006 American Journal of Cardiology and called for screening of all men 45 to 75 and all women 55 to 74 who are more than minimally at risk for heart attack or stroke. Legislation has been introduced in Texas that would require insurance companies to cover the tests. (JAMA. 2008;299:208-10) The lead author and founder of the organization, Morteza Naghavi, advises and receives research support from Pfizer, manufacturer of cholesterol-reducing Lipitor, and consults for and owns stock in Endothelix, which makes a fingertip thermal measuring device that purports to reveal heart attack risk. Twelve of 26 guideline co-authors disclosed ties to drug and imaging equipment manufacturers. (Am J Cardiol. 2006;98:2-15.)(http://www.cspinet.org/new/pdf/20080109_shape_conflict_of_interest_disclosure_statement.pdf, accessed 1/15/08)

Five of 13 board members of SHAPE also have financial ties with the industry. (http://www.shapesociety.org/site/c.iuIRL8MVJxE/b.2815275/, accessed 1/16/08; and (http://www.cspinet.org/new/pdf/20080109_shape_conflict_of_interest_disclosure_statement.pdf, accessed 1/15/08)

•Morteza Naghavi, M.D., advisor to Pfizer and diaDexus Inc.; a consultant to Endothelix Inc. and Volcano Corp.; received research support from Pfizer; shareholder in Endothelix and Volcano.

•Harvey Hecht, M.D., on the speakers bureau for Kos Pharmaceuticals and Pfizer; a consultant to Endothelix and Phillips.

•Erling Falk, M.D., a consultant to Endothelix.

•Matthew Budoff, M.D., member of the speakers bureau for GE Healthcare; a consultant for Endothelix.

•Daniel Berman, M.D., member of the speakers bureau for Astellas Pharma; a consultant for Bristol-Myers Squibb; received research/grant support from Astellas Pharma, Bristol-Myers Squibb, and Tyco Healthcare.


 
[Integrity in Science] [CSPI U.S.] Back to Top